CRIXIVAN CAPSULE

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

INDINAVIR (INDINAVIR SULFATE)

Prieinama:

MERCK CANADA INC

ATC kodas:

J05AE02

INN (Tarptautinis Pavadinimas):

INDINAVIR

Dozė:

300MG

Vaisto forma:

CAPSULE

Sudėtis:

INDINAVIR (INDINAVIR SULFATE) 300MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

100

Recepto tipas:

Prescription

Gydymo sritis:

HIV PROTEASE INHIBITORS

Produkto santrauka:

Active ingredient group (AIG) number: 0133330004; AHFS:

Autorizacija statusas:

CANCELLED PRE MARKET

Leidimo data:

2016-11-01

Prekės savybės

_ _
_Product Monograph - CRIXIVAN_
_®_
_ _
_Page 1 of 45_
PRODUCT MONOGRAPH
PR
CRIXIVAN
®
indinavir sulfate capsules
100, 200, 300, and 400 mg
(as indinavir)
HIV Protease Inhibitor
MERCK FROSST CANADA LTD.
16711 Trans Canada Highway
KIRKLAND QC H9H 3L1
Canada
www.merckfrosst.com
Date of Revision:
February 13, 2007
SUBMISSION CONTROL NO: 110356
CRIXIVAN is a
®
Registered Trademark of Merck & Co., Inc.
Used under licence.
_ _
_Product Monograph - CRIXIVAN_
_®_
_ _
_Page 2 of 45_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT
INFORMATION........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE
REACTIONS...................................................................................................
8
DRUG INTERACTIONS
.................................................................................................
14
DOSAGE AND ADMINISTRATION
.............................................................................
20
OVERDOSAGE................................................................................................................
22
ACTION AND CLINICAL
PHARMACOLOGY............................................................
22
STORAGE AND STABILITY
.........................................................................................
25
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................. 26
PART II: SCIENTIFIC INFORMATION
..............................................................................
27
PHARMACEUTICAL
INFORMATION.........................................................................
27
CLINICAL TRIALS
...